AF
CTKB icon

Allworth Financial’s Cytek Biosciences CTKB Stock Holding History

Allworth Financial’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.23K Sell
1,181
-209
-15% -$892 ﹤0.01% 4101
2026
Q1 		$6.08K Buy
1,390
+341
+33% +$1.61K ﹤0.01% 3841
2025
Q4 		$5.3K Buy
1,049
+52
+5% +$241 ﹤0.01% 3664
2025
Q3 		$3.46K Buy
997
+680
+215% +$2.55K ﹤0.01% 3743
2025
Q2 		$1.08K Buy
+317
New +$1.06K ﹤0.01% 3942
2025
Q1 		– Sell
-98
Closed -$566 – 4085
2024
Q4 		$566 Hold
98
– – ﹤0.01% 3565
2024
Q3 		$543 Buy
+98
New +$556 ﹤0.01% 3397
2024
Q1 		– Sell
-41
Closed -$374 – 3621
2023
Q4 		$374 Buy
+41
New +$258 ﹤0.01% 3193

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Allworth Financial's CTKB Position: Q2 2026 in Review

Allworth Financial reduced its Cytek Biosciences (CTKB) stake by 15% in Q2 2026, selling an estimated $892 and leaving 1,181 shares worth $5.23K. The position accounts for ﹤0.01% of the portfolio, ranked #4101.

Allworth Financial first reported a position in CTKB in Q4 2023 and has held it in 8 quarters since. The position peaked at $6.08K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Allworth Financial held 1,181 shares of Cytek Biosciences worth $5.23K as of Q2 2026.
  • Allworth Financial sold 209 Cytek Biosciences shares in Q2 2026, an estimated $892.
  • Cytek Biosciences made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4101 holding.
  • Allworth Financial first reported a position in Cytek Biosciences in Q4 2023 and has held it in 8 quarters since.
  • Allworth Financial's Cytek Biosciences position peaked at $6.08K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.